Following the approval of the first monoclonal antibody in 1986, the approval and sales were flat until the introduction of the first chimeric monoclonal antibodies. Further approvals of humanized and fully human monoclonal antibodies, the market for therapeutic monoclonal antibodies experienced a significant surge to become a multi-billion dollar market in the current decade.

View full report @

With over 300 monoclonal antibody candidates under assessment, this segment will continue to drive the sales of biopharmaceutical products. The number of monoclonal antibody products being made commercially available is rising consistently with an addition of 3-5 products every year.

Perpetually expanding interest in antibody product development is significantly driven by progress in our understanding of diseases. Areas such as proteomics and genomics others continue to provide newer targets for disease modulation. Monoclonal antibodies are claimed to provide the fastest route of clinical proof of concept for inhibition, blocking or activation of new targets.

Download Sample research report with TOC and Figures @

Since production of monoclonal antibody products is easily open for several platform-based approaches and the antibodies are mostly well-tolerated and specific, the risk of safety issues in human clinical trials of monoclonal antibody products is rare. Hence after successful proof of concept studies with these products, they are observed to undergo rapid commercialization, hence gaining first-to-market advantage.

Another factor facilitating the growth of this market is the overall expansion of global pharmaceuticals market resulting from growth in senescent population and evolving standard of living in emerging economies.

The global platelet rich plasma market is segmented on the following bases:

  1. Top Drugs Humira, Enbrel, Rituxan, Remicade, Herceptin, Avastin, Neulasta, Lucentis, Avonex, Rebif, Others
  2. Molecule Type mAb, Protein
  3. Geography North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Do inquiry before purchase the Industry Research Report @

Key players identified for therapeutic monoclonal antibodies market include but are not limited to: Abbott Laboratories, AbbVie Inc., Amgen, Inc., AstraZeneca, Bayer AG, Biogen Inc., Bristol Myers Squibb Co., Daiichi Sankyo Company, Ltd., Eli Lilly and Company, GlaxoSmithKline Plc., Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi Genzyme, Thermo Fisher Scientific, Inc. and several others

Read more


No comments to display.

Related posts

Global Vehicle Alarm System Market to Witness Soaring Growth During 2018-2028

A security system is always a perfect way to protect your vehicle from external sources. Vehicle alarm system is the technology to protect your vehicle from theft, the system works by creating loud noise or sometimes by flashing of lights from the vehicles offering a prompt response to the owner so that he can reach to his car.

Weatherization Services Market To Register a CAGR 3.8 % During 2018-2028

Future Market Insights has announced the addition of the “Weatherization Services Market Global Industry Analysis 2018 - 2028 " report to their offering

Cloud-Based ITSM Market to Reflect Impressive Growth Rate by 2021

The report titled, “Cloud-Based ITSM Market” published by MarketsandMarkets provides an extraordinary analysis for evaluating the Cloud-Based ITSM Industry, highlighting opportunities and supporting strategic and skilful decision-making.

Urology Imaging Systems Market projects substantial growth potential with CAGR of 3.8% over 2018-2028

Urology Imaging Systems Market: Rising Popularity of Portable Imaging Tools to Trigger Innovation: Global Industry Analysis and Opportunity Assessment 2018-2028